Thermo Fisher Scientific Inc. $TMO Shares Sold by Oakworth Capital Inc.

Oakworth Capital Inc. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,089 shares of the medical research company’s stock after selling 311 shares during the quarter. Oakworth Capital Inc.’s holdings in Thermo Fisher Scientific were worth $847,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Mondrian Investment Partners LTD lifted its stake in Thermo Fisher Scientific by 146.1% during the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after purchasing an additional 127,357 shares in the last quarter. Foresight Group Ltd Liability Partnership lifted its stake in Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after acquiring an additional 56,747 shares in the last quarter. Advisors Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock valued at $63,201,000 after acquiring an additional 7,967 shares during the period. New England Research & Management Inc. grew its position in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock valued at $1,033,000 after acquiring an additional 567 shares in the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co lifted its position in shares of Thermo Fisher Scientific by 5.3% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company’s stock worth $33,488,000 after purchasing an additional 3,400 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TMO shares. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $588.35.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.1%

Thermo Fisher Scientific stock opened at $464.18 on Monday. The stock’s fifty day moving average is $476.70 and its two-hundred day moving average is $447.15. The stock has a market cap of $175.28 billion, a PE ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.